Cart
sales@molnova.com
Obtusifolin 2-O-β-D-glucoside
CAS No. 120163-18-0
Obtusifolin 2-O-β-D-glucoside( ——— )
Catalog No. M38237 CAS No. 120163-18-0
Obtusifolin-2-O-glucoside (compound 7) is a Tyrosinase inhibitor (IC50=9.2 μM). Obtusifolin-2-O-glucoside can be isolated from cassia seed.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 25MG | Get Quote | In Stock |
|
| 50MG | Get Quote | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameObtusifolin 2-O-β-D-glucoside
-
NoteResearch use only, not for human use.
-
Brief DescriptionObtusifolin-2-O-glucoside (compound 7) is a Tyrosinase inhibitor (IC50=9.2 μM). Obtusifolin-2-O-glucoside can be isolated from cassia seed.
-
DescriptionObtusifolin-2-O-glucoside (compound 7) is a Tyrosinase inhibitor (IC50=9.2 μM). Obtusifolin-2-O-glucoside can be isolated from cassia seed.
-
In Vitro———
-
In Vivo———
-
Synonyms———
-
PathwayOthers
-
TargetOther Targets
-
RecptorIC50: 9.2 μM (Tyrosinase)
-
Research Area———
-
Indication———
Chemical Information
-
CAS Number120163-18-0
-
Formula Weight446.4
-
Molecular FormulaC22H22O10
-
Purity>98% (HPLC)
-
Solubility———
-
SMILES———
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Lee GY, et al. Tyrosinase inhibitory components from the seeds of Cassia tora. Arch Pharm Res. 2018 May;41(5):490-496. ?
molnova catalog
related products
-
AA41612
AA41612 is a novel antagonist of melanopsin-mediated phototransduction.
-
2F-Peracetyl-Fucose
2F-Peracetyl-Fucose (1,3,4-Tri-O-acetyl-2-deoxy-2-fluoro-L-fucopyranos) is a potent fucosyltransferase (FUT) inhibitor that suppresses salivary acidification and fucosylation in an in vitro inflammatory model.
-
Burosumab
Burosumab(KRN23) is a human monoclonal antibody targeting fibroblast growth factor 23 (FGF23) for the treatment of cutaneous-skeletal hypophosphatemic syndrome (CSHS) and tumor-induced osteochondrosis.
